Downstream targets of the IL‐6 cascade, such as Janus tyrosine kinase 1 and 2 (JAK1/2) and Signal transducer and activator of transcription 3 (STAT3) are also being clinically evaluated for their anti‐tumor efficacy in BC.94, 95, 97, 98. Here, STAT3 is linked to neoplasm.